alimera.png
Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences
07 mai 2024 08h00 HE | Alimera Sciences, Inc.
ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
alimera.png
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
07 mars 2024 07h30 HE | Alimera Sciences, Inc.
Q4 Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE NEWSWIRE)...
alimera.png
Alimera Completes Recruitment for the Synchronicity Study
04 janv. 2024 08h00 HE | Alimera Sciences, Inc.
ATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Todd Wood
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12 déc. 2023 07h30 HE | Alimera Sciences, Inc.
ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients,...
alimera.png
Alimera Sciences Reports Third Quarter 2023 Results
26 oct. 2023 07h00 HE | Alimera Sciences, Inc.
Net Revenue up 72% to $23.4 Million vs. Q3 2022Net Loss Decreased by 74% to $1.4 Million vs. Q3 2022Adjusted EBITDA of $5.4 Million in Q3 2023Successful Integration of YUTIQ into the U.S. Segment ...
alimera.png
Alimera Acquires U.S. Commercial Rights to YUTIQ®
18 mai 2023 07h00 HE | Alimera Sciences, Inc.
Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023 Alimera projects at least $100 million of consolidated net revenue and over $20 million of Adjusted EBITDA* in 2024...